Research Topics
| Guadalupe Garcia-TsaoSummaryAffiliation: Yale University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascitesGuadalupe Garcia-Tsao
Yale University School of Medicine, New Haven, CT 06510, USA
Nat Clin Pract Gastroenterol Hepatol 3:380-9. 2006....
Portal hypertension and hepatocellular carcinoma: prognosis and beyondPuneeta Tandon
Clin Gastroenterol Hepatol 4:1318-9. 2006
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosisGuadalupe Garcia-Tsao
Section of Digestive Diseases, Yale University School of Medicine and VA-CT Healthcare System, New Haven, Connecticut 06520, USA
Am J Gastroenterol 102:2086-102. 2007
Probiotics and liver diseaseAnish A Sheth
Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520 8000, USA
J Clin Gastroenterol 42:S80-4. 2008..The role of probiotics is examined in the following areas: a) prevention of infection, b) the hyperdynamic circulatory state of cirrhosis, c) hepatic encephalopathy, d) liver function, and e) nonalcoholic fatty liver disease...
Liver disease in patients with hereditary hemorrhagic telangiectasiaG Garcia-Tsao
Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn 06520, USA
N Engl J Med 343:931-6. 2000..Liver involvement in patients with this disease has not been fully characterized...
Portal hypertensionGuadalupe Garcia-Tsao
Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06510, USA
Curr Opin Gastroenterol 21:313-22. 2005..Report on significant advances in the pathophysiology, diagnosis, and management of the complications of portal hypertension that have occurred in the last year...
Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C ProgramGuadalupe Garcia-Tsao
Department of Veterans Affairs Medical Center, West Haven, Connecticut, USA
Am J Gastroenterol 104:1802-29. 2009..A rational management of cirrhosis will result in improvements in quality of life, treatment adherence, and, ultimately, in outcomes...
Liver involvement in hereditary hemorrhagic telangiectasia (HHT)Guadalupe Garcia-Tsao
Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine and VA CT Healthcare System, 333 Cedar Street 1080 LMP, P O Box 208019, New Haven, CT 06520, USA
J Hepatol 46:499-507. 2007..Papers were considered if they were published in English and if they included specific cases that were sufficiently described...
Portal hypertensionGuadalupe Garcia-Tsao
Section of Digestive Diseases, Yale University School of Medicine and Connecticut VA, Healthcare System, New Haven, 06510, USA
Curr Opin Gastroenterol 22:254-62. 2006..Significant advances in the pathophysiology, diagnosis and management of the complications of portal hypertension that have occurred in the last year are reported...
Acute kidney injury in cirrhosisGuadalupe Garcia-Tsao
Section of Digestives Diseases, Yale University School of Medicine, New Haven, CT, USA
Hepatology 48:2064-77. 2008..Vasoconstrictors are useful bridging therapies in HRS. Ultimately, liver transplantation is indicated in otherwise reasonable candidates in whom AKI does not resolve with specific therapy...
Preventing the development of varices in cirrhosisGuadalupe Garcia-Tsao
Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA
J Clin Gastroenterol 41:S300-4. 2007....
Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conferenceGuadalupe Garcia-Tsao
Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
Hepatology 47:1764-72. 2008
Bacterial infections in cirrhosis: treatment and prophylaxisGuadalupe Garcia-Tsao
Department of Digestive Diseases, Yale University, New Haven, CT 06620, USA
J Hepatol 42:S85-92. 2005
Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertensionCristina Ripoll
Guadalupe Garcia Tsao, MD Digestive Diseases Section, Yale University School of Medicine, 333 Cedar Street 1080 LMP, New Haven, CT 06510, USA
Curr Treat Options Gastroenterol 10:483-94. 2007..Preliminary data suggest that cryotherapy may be a reasonable option for diffuse GAVE lesions. Neither beta-blockers nor TIPS reduces the bleeding risk in patients with GAVE and thus should not be used in this setting...
Difficult management decisionGuadalupe Garcia-Tsao
Liver Study Unit, Yale School of Medicine, New Haven, Connecticut 06520, USA
J Clin Gastroenterol 35:S143-6. 2002
Gut microflora in the pathogenesis of the complications of cirrhosisGuadalupe Garcia-Tsao
Gastroenterology Service, VA Connecticut Healthcare System and Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street 1080 LMP, P O Box 3333, New Haven, CT 06520 8019, USA
Best Pract Res Clin Gastroenterol 18:353-72. 2004..This chapter presents evidence regarding gut flora and its modification in the pathogenesis and management of these complications of cirrhosis...
Bacterial infections in cirrhosisGuadalupe Garcia-Tsao
Yale University School of Medicine, New Haven, Connecticut 06520 8019, USA
Can J Gastroenterol 18:405-6. 2004..Patients who recover from an episode of SBP should be given long term prophylaxis with norfloxacin and should be assessed for liver transplantation...
Spontaneous bacterial peritonitis: a historical perspectiveGuadalupe Garcia-Tsao
Yale University School of Medicine and CT-VA Healthcare System, 333 Cedar Street, New Haven, CT 06510, USA
J Hepatol 41:522-7. 2004
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosisCristina Ripoll
Veterans Affairs CT Healthcare System, West Haven, CT 06516, USA
J Hepatol 50:923-8. 2009..Predictors of the development of hepatocellular carcinoma (HCC), including hepatic venous pressure gradient (HVPG) were analyzed...
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis CRobert J Fontana
Department of Internal Medicine, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan, USA
Gut 59:1401-9. 2010..The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC)...
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1Thomas D Boyer
Liver Research Institute, Department of Internal Medicine, University of Arizona College of Medicine, Tucson, AZ 85724, USA
Liver Transpl 17:1328-32. 2011..For patients not undergoing transplantation, HRS reversal with terlipressin and/or albumin improves survival...
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosisCristina Ripoll
Veterans Affairs CT Healthcare System, Yale University School of Medicine, West Haven, Connecticut 06516, USA
Gastroenterology 133:481-8. 2007....
What do patients consider when making decisions about treatment for hepatitis C?Liana Fraenkel
Department of Medicine, VA Connecticut Healthcare System, West Haven, Conn, USA
Am J Med 118:1387-91. 2005..In this study, we sought to investigate the factors that influence patients' decisions as they consider treatment for hepatitis C infection...
Patients' preferences for treatment of hepatitis CLiana Fraenkel
VA Connecticut Healthcare System and Yale University School of Medicine, New Haven, Connecticut, USA
Med Decis Making 30:45-57. 2010..The objective of this study was to ascertain patient preferences for treatment of hepatitis C virus (HCV)...
Quantitative histological-hemodynamic correlations in cirrhosisSupatsri Sethasine
Section of Digestive Diseases, Yale University and VA CT Healthcare System, West Haven, CT, USA
Hepatology 55:1146-53. 2012..Beyond pathophysiological implications, this also has methodological implications that are discussed in this article...
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosisRoberto J Groszmann
Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516, USA
N Engl J Med 353:2254-61. 2005..ClinicalTrials.gov number, NCT00006398.)..
Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis CRichard W Lambrecht
Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA
Gastroenterology 140:1490-500.e3. 2011..Our aim was to assess the relationship of iron and HFE genetic variations to progression and outcomes in the HALT-C Trial and whether PegIFN therapy influenced iron variables...
Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosisPuneeta Tandon
Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Clin Gastroenterol Hepatol 8:546-9. 2010..The aim of this study was to evaluate the effect of sildenafil on systemic and portal hemodynamics in an open-label pilot study...
Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosisSatish Nagula
Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
J Hepatol 44:111-7. 2006....
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis CAnna S Lok
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA
Hepatology 54:434-42. 2011..In the United States, neither previous nor occult HBV infection is an important factor in HCC development among patients with advanced chronic hepatitis C...
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosisGuadalupe Garcia-Tsao
Section of Digestive Diseases, Yale University School of Medicine and VACT Healthcare System, New Haven, CT, USA
Hepatology 46:922-38. 2007
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndromeArun J Sanyal
Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
Gastroenterology 134:1360-8. 2008..The aim of this study was to evaluate the efficacy and safety of terlipressin, a systemic arterial vasoconstrictor, for cirrhosis type 1 HRS...
Portal hypertension: from the patient to the molecule and back: a symposium honoring Roberto J. Groszmann, MDGuadalupe Garcia-Tsao
Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520-8019, USA
J Clin Gastroenterol 41:S243-4. 2007
A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhageAnna V Longacre
Section of Digestive Disease, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
Hepatology 47:169-76. 2008..Physicians should discuss both EVL and beta-blockers with patients requiring primary prophylaxis for variceal hemorrhage. Future guidelines should incorporate individual patient preferences...
A commonsense approach to esophageal varicesAnna V Longacre
Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, 1080 LMP, 333 Cedar Street, New Haven, CT 06520, USA
Clin Liver Dis 10:613-25, x. 2006..This article describes a practical approach to the management of cirrhotic patients who have gastroesophageal varices...
Managing varices: drugs, bands, and shuntsChristopher Kenneth Opio
Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street 1080 LMP, New Haven, CT 06510, USA
Gastroenterol Clin North Am 40:561-79. 2011..However, the specific use of each of these therapies depends on the setting (primary or secondary prophylaxis, treatment of AVH) and on patient characteristics. The indications for each are summarized in Table 4...
Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitisPuneeta Tandon
Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Clin Gastroenterol Hepatol 9:260-5. 2011..To improve stratification of patient care, we performed a systematic review to identify the most robust predictors of mortality in cirrhotic patients with SBP...
Clinical pharmacology of portal hypertensionCecilia Minano
Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT 06520, USA
Gastroenterol Clin North Am 39:681-95. 2010..This article reviews the pathophysiologic bases of the different pharmacologic treatments for portal hypertension in patients with cirrhosis and places them in the context of the natural history of varices and variceal hemorrhage...
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studiesPuneeta Tandon
Digestive Diseases Section, Yale University School of Medicine, New Haven, CT, USA
Liver Int 29:502-10. 2009..Although there are many studies of the predictors of death in hepatocellular carcinoma (HCC), most combine patients with and without cirrhosis and many combine those with compensated and decompensated cirrhosis...
Hepatic vascular malformations in hereditary hemorrhagic telangiectasiaSakib Karim Khalid
Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Semin Liver Dis 28:247-58. 2008..Patients who fail aggressive medical therapy and those with acute biliary/hepatic necrosis should be considered for liver transplantation...
Liver involvement in hereditary hemorrhagic telangiectasia: CT and clinical findings do not correlate in symptomatic patientsJim S Wu
Department of Diagnostic Radiology, Yale University School of Medicine and Yale-New Haven Hospital, New Haven, CT, USA
AJR Am J Roentgenol 187:W399-405. 2006..Multiphasic CT is useful in diagnosing liver involvement due to HHT; however, no strong correlation was seen between CT findings and the clinical subtype of HHT liver disease...
Prevention and treatment of infections in patients with cirrhosisSahar Ghassemi
Division of Digestive Diseases, Yale University School of Medicine, VA CT Healthcare System, 333 Cedar St 1080 LMP, PO Box 208019, New Haven, CT 06520, USA
Best Pract Res Clin Gastroenterol 21:77-93. 2007....
Recommendations for probiotic use--2008Martin H Floch
Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520 8019, USA
J Clin Gastroenterol 42:S104-8. 2008..Many reports in the "C" recommendations were significant but fell short of receiving stronger ratings because of the size of reported patient studies, and also the factors that limited categories to the "B" rating...
The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesisKhurram Bari
Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut Digestive Diseases, Veterans Administration Connecticut Healthcare System, West Haven, Connecticut
Clin Gastroenterol Hepatol 10:1169-75. 2012..Vasoconstrictors could be used instead of albumin and, with longer use, prevent PCD and delay ascites recurrence...
Treatment of portal hypertensionKhurram Bari
Khurram Bari, Guadalupe Garcia Tsao, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT and VA Connecticut Healthcare System, West Haven, CT 06520, United States
World J Gastroenterol 18:1166-75. 2012..Prevention of recurrent variceal hemorrhage consists of the combination of β-blockers and endoscopic band ligation...
Patients' experiences related to anti-viral treatment for hepatitis CLiana Fraenkel
VA Connecticut Healthcare System, CT, USA
Patient Educ Couns 62:148-55. 2006..To conduct a qualitative study to elicit patients' descriptions of their own experiences with treatment for hepatitis C (HCV)...
Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic ratsReiner Wiest
Hepatic Hemodynamic Laboratory, Veterans Administration Medical Center, West Haven, CT 06515, USA
Hepatology 38:1508-15. 2003..69, P <.01). In conclusion, in cirrhotic animals BT appears to lead to endotoxemia, stimulation of GTPCH-I, increased BH(4) synthesis, and further enhancement of vascular NO production that leads to aggravation of vasodilatation...
Refractory ascites and hepatorenal syndromeGuadalupe Garcia-Tsao
Yale University School of Medicine, New Haven, Cennecticut, USA
Rev Gastroenterol Mex 69:152-4. 2004
Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosisSakib K Khalid
Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Clin Gastroenterol Hepatol 7:994-9; quiz 913-4. 2009..We performed a prospective, case-control study to investigate the effects of analgesics on acute hepatic decompensation...
High Prevalence of Antibiotic-Resistant Bacterial Infections Among Patients With Cirrhosis at a US Liver CenterPuneeta Tandon
University of Alberta, Edmonton, Alberta, Canada Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
Clin Gastroenterol Hepatol 10:1291-8. 2012..Exposure to systemic antibiotics is a risk factor for AR-BI; however, little is known about the effects of the increasingly used oral nonabsorbed antibiotics...
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosisRobert J Fontana
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
Clin Gastroenterol Hepatol 7:219-26. 2009..Serum fibrosis marker levels during the lead-in treatment phase of patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial were determined...
Bacterial translocation (BT) in cirrhosisReiner Wiest
Department of Internal Medicine I, University of Regensburg Hospital Franz-Josef-Strauss-Allee, Regensburg, Germany
Hepatology 41:422-33. 2005..Future research in the field of BT in cirrhosis will allow the development of new therapeutic targets in the prevention of infections and other complications of cirrhosis...
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosisPere Gines
Liver Unit, Hospital Clinic, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, University of Barcelona, Instituto Reina Sofia de Investigacion Nefrologica, Barcelona, Catalunya, Spain
Gastroenterology 123:1839-47. 2002..However, its effect on survival and healthcare costs is still uncertain...
Spontaneous bacterial peritonitisGuadalupe Garcia-Tsao
Rev Gastroenterol Mex 70:66-8. 2005
Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference?Roberto J Groszmann
Gastroenterology 123:1388-91. 2002
Bacterial infections, sepsis, and multiorgan failure in cirrhosisPuneeta Tandon
Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada
Semin Liver Dis 28:26-42. 2008..We review the pathogenesis and management of these complications, the role of adrenal insufficiency, and the utility of intensive care prognostic models...
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosisAmir A Qamar
Brigham and Women s Hospital, Boston, MA 02446, USA
Hepatology 47:153-9. 2008..Patients with mild portal hypertension whose PLT remains greater than 100,000 have significantly less risk of GEV. Although HVPG correlates somewhat with PLT, changes in PLT cannot be used as a surrogate for HVPG changes...
Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United StatesMarion G Peters
University of California at San Francisco, San Francisco, CA 94143 0538, USA
Hepatology 46:769-75. 2007..Possible mechanisms underlying this health discrepancy are not clear, but increased awareness of PBC as a cause of chronic cholestatic liver disease is critical in evaluating non-Caucasian patients in the United States...
Multiple angiomyolipomata of the liver: a case reportLaura H Tang
Department of Anatomic Pathology, Yale University School of Medicine, New Haven, Connecticut 06511, USA
Mod Pathol 15:167-71. 2002..While the histologic diagnosis of AML in a surgical resection specimen is often straightforward, the radiographic, cytologic and intra-operative interpretation of a case with multiple lesions presents a considerable challenge...
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assayMarlyn J Mayo
University of Texas Southwestern Medical Center, Dallas, TX 75390 9151, USA
Hepatology 48:1549-57. 2008..CONCLUSION: The ELF algorithm is a highly accurate noninvasive measure of PBC disease severity that provides useful long-term prognostic information...
Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: in search of predictors of significant diseaseGuadalupe Garcia-Tsao
Hepatology 48:1377-9. 2008
Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosisBurton Combes
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9151, USA
Am J Gastroenterol 99:264-8. 2004....
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosisBurton Combes
The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9151, USA
Hepatology 42:1184-93. 2005..In conclusion, methotrexate when added to UDCA for a median period of 7.6 years had no effect on the course of PBC treated with UDCA alone...
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studiesGuadalupe Garcia-Tsao
Gastroenterology Unit, Ospedale Cervello and University of Palermo, Italy
J Hepatol 44:217-31. 2006
Research Grants
- CIRRHOSIS AND ITS COMPLICATIONSGuadalupe Garcia Tsao; Fiscal Year: 2007..Renewal of the award will allow Dr. Garcia-Tsao to maintain both POR and her mentoring endeavors to their fullest extent so she can continue to make significant contributions in the field of chronic liver disease and its complications. ..
